Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by MyKnighton Jan 14, 2020 12:19pm
63 Views
Post# 30551320

RE:RE:Why can’t they close one deal

RE:RE:Why can’t they close one dealFirst Echelon is driving the Deal/Licence conversations, and as explain on previous post multiple scenario can happen with multiple offers.
  • Buy out
    • With a Bid war
    • Licence right
    • Does Kal-1816 is include
  • Licence/royalties
    • Establish the rules
    • Europe market how/who...
  • Partneship
    • with licence and royalties.
    • Where does the licence apply.
    • ...
This being said no information can go out until all the detail are flush out, and buy law you don't want anything to go out that would give an advantage to anybody.

Does big player won't sign until they have everything figure out.

Simple enough... 

RE:Why can’t they close one deal

I can't figure that one out either. Could it be that interested parties don't like their debt situation? I think it's a small price to pay when you consider the future value of the therapy. Any other ideas?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities